Literature DB >> 10405569

[Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome].

A Undas1, J Swadźba, R Undas, J Musiał.   

Abstract

We report the case of a 43-year-old woman with systemic lupus erythematosus who survived three episodes of catastrophic antiphospholipid syndrome. During the first episode symptoms involved predominantly the central nervous system, whilst during the second episode of multiorgan failure, the cardiovascular system, lungs and kidneys were particularly affected. Twenty months later, the patient experienced an acute exacerbation of chronic renal failure and later, died of massive pulmonary embolism. The characteristic findings of antiphospholipid syndrome included persistently high titers of IgG anticardiolipin antibodies, positive lupus anticoagulant, and microcytic anaemia with a distinct haemolytic component.

Entities:  

Mesh:

Year:  1998        PMID: 10405569

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  4 in total

Review 1.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 2.  Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Authors:  Silvia Bucciarelli; Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Recurrent episodes of hemorrhagic alveolitis in relapsing catastrophic antiphospholipid syndrome: the same side of the dark moon.

Authors:  Filippo Pieralli; Maddalena Grazzini; Vieri Vannucchi; Antonio Mancini; Daniele Cammelli; Carlo Nozzoli
Journal:  Clin Rheumatol       Date:  2013-12-21       Impact factor: 2.980

Review 4.  Antiphospholipid syndrome infectious origin.

Authors:  M Blank; R A Asherson; R Cervera; Y Shoenfeld
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.542

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.